Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial.

Authors: Earl, H.M., Hickish, T. et al.

Journal: JOURNAL OF CLINICAL ONCOLOGY

Volume: 34

Issue: 15

eISSN: 1527-7755

ISSN: 0732-183X

DOI: 10.1200/JCO.2016.34.15_suppl.1014

Source: Web of Science (Lite)